1 of 1
Story summary
- A Nature study finds that Alzheimer's risk is largely determined by the apolipoprotein E (APOE) gene, with APOE4 increasing risk and APOE2 offering protection.
- About 28% of people carry high-risk APOE variants, indicating potential for gene-therapy targeting these variants.
- Lexeo Therapeutics is developing therapies that could benefit many, but efficacy proof and regulatory hurdles remain.
- Experts say a combination of treatments may be necessary for effective Alzheimer's management.
